Our mission is to revolutionize the treatment of cancer by developing novel therapies that harness the power of a patient’s own immune system.
Immunotherapy has emerged as one of the most promising advancements to improve treatment outcomes for patients with cancer.
We take a combination treatment approach and administer checkpoint inhibitors alongside our cancer-fighting, T-cell activation and co-stimulation therapies.
Heat Biologics a biopharmaceutical company that develops immunotherapies to activate a patient’s immune system against cancer through T-cell activation. Our proprietary, T-cell Activation Platform (TCAP) produces therapies designed to turn “cold” tumors “hot,” and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase effectiveness. We are currently enrolling patients in our Phase 2 clinical trial for non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®). We also have numerous pre-clinical programs at various stages of development.